» Articles » PMID: 37232840

Fiducial Markers Allow Accurate and Reproducible Delivery of Liver Stereotactic Body Radiation Therapy

Overview
Journal Curr Oncol
Publisher MDPI
Specialty Oncology
Date 2023 May 26
PMID 37232840
Authors
Affiliations
Soon will be listed here.
Abstract

Fiducial markers are utilized for image guided radiotherapy (IGRT) alignment during the delivery of liver stereotactic body radiosurgery (SBRT). There are limited data demonstrating the impact of matching fiducials on the accuracy of liver SBRT. This study quantifies the benefit of fiducial-based alignment and improvements in inter-observer reliability. Nineteen patients with 24 liver lesions were treated with SBRT. Target localization was performed using fiducial markers on cone-beam computed tomography (CBCT). Each CBCT procedure was retrospectively realigned to match both the liver edge and fiducial markers. The shifts were recorded by seven independent observers. Inter-observer variability was analyzed by calculating the mean error and uncertainty for the set-up. The mean absolute Cartesian error observed from fiducial and liver edge-based alignment was 1.5 mm and 5.3 mm, respectively. The mean uncertainty from fiducial and liver edge-based alignment was 1.8 mm and 4.5 mm, respectively. An error of 5 mm or greater was observed 50% of the time when aligning to the liver surface versus 5% of the time when aligning to fiducial markers. Aligning to the liver edge significantly increased the error, resulting in increased shifts when compared to alignment to fiducials. Tumors of 3 cm or farther from the liver dome had higher mean errors when aligned without fiducials (4.8 cm vs. 4.4 cm, = 0.003). Our data support the use of fiducial markers for safer and more accurate liver SBRT.

Citing Articles

Daily Diagnostic Quality Computed Tomography-on-Rails (CTOR) Image Guidance for Abdominal Stereotactic Body Radiation Therapy (SBRT).

Martin-Paulpeter R, Jensen P, Perles L, Sawakuchi G, Das P, Koay E Cancers (Basel). 2024; 16(22).

PMID: 39594725 PMC: 11591933. DOI: 10.3390/cancers16223770.


Customizable Lyophilized Agent for Radiotherapy Imaging and TherapY (CLARITY).

Moreau M, China D, Sy G, Ding K, Ngwa W J Funct Biomater. 2024; 15(10).

PMID: 39452584 PMC: 11508613. DOI: 10.3390/jfb15100285.


Assessment of real-time US-CT/MR-guided percutaneous gold fiducial marker implementation in malignant hepatic tumors for stereotactic body radiation therapy.

Hwang S, Chun S, Chie E, Lee J J Liver Cancer. 2024; 24(2):263-273.

PMID: 38853440 PMC: 11449585. DOI: 10.17998/jlc.2024.06.03.

References
1.
Mathew A, Atenafu E, Owen D, Maurino C, Brade A, Brierley J . Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion. Eur J Cancer. 2020; 134:41-51. PMC: 7340168. DOI: 10.1016/j.ejca.2020.04.024. View

2.
Seppenwoolde Y, Wunderink W, Wunderink-van Veen S, Storchi P, Mendez Romero A, Heijmen B . Treatment precision of image-guided liver SBRT using implanted fiducial markers depends on marker-tumour distance. Phys Med Biol. 2011; 56(17):5445-68. DOI: 10.1088/0031-9155/56/17/001. View

3.
Rusthoven K, Kavanagh B, Cardenes H, Stieber V, Burri S, Feigenberg S . Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009; 27(10):1572-8. DOI: 10.1200/JCO.2008.19.6329. View

4.
Bertholet J, Worm E, Hoyer M, Poulsen P . Cone beam CT-based set-up strategies with and without rotational correction for stereotactic body radiation therapy in the liver. Acta Oncol. 2017; 56(6):860-866. DOI: 10.1080/0284186X.2017.1288925. View

5.
Goodman K, Kavanagh B . Stereotactic Body Radiotherapy for Liver Metastases. Semin Radiat Oncol. 2017; 27(3):240-246. DOI: 10.1016/j.semradonc.2017.02.004. View